tiprankstipranks
Advertisement
Advertisement

CLVLF Stock Latest News

Clinuvel Leverages AAD 2026 to Advance Vitiligo, EPP Strategy and U.S. Profile
Company AnnouncementsClinuvel Leverages AAD 2026 to Advance Vitiligo, EPP Strategy and U.S. Profile
8d ago
Clinuvel Showcases AI Vitiligo Tool and EPP Therapy at Major U.S. Dermatology Meeting
PremiumCompany Announcements
Clinuvel Showcases AI Vitiligo Tool and EPP Therapy at Major U.S. Dermatology Meeting
14d ago
Clinuvel Backs CEO Wolgen as Cash-Rich Biotech Prioritises Vitiligo Push
PremiumCompany Announcements
Clinuvel Backs CEO Wolgen as Cash-Rich Biotech Prioritises Vitiligo Push
21d ago
Clinuvel Profit Dips on Higher Expansion Costs Despite Record Half-Year Revenue
PremiumCompany Announcements
Clinuvel Profit Dips on Higher Expansion Costs Despite Record Half-Year Revenue
1M ago
Clinuvel Flags Wide-Ranging Risks Ahead of Institutional Investor Meetings
PremiumCompany Announcements
Clinuvel Flags Wide-Ranging Risks Ahead of Institutional Investor Meetings
2M ago
Clinuvel Starts Preclinical Dosing of New Controlled-Release Peptide Platform VLRX-L
PremiumCompany AnnouncementsClinuvel Starts Preclinical Dosing of New Controlled-Release Peptide Platform VLRX-L
3M ago
Clinuvel Reports New Positive Vitiligo Data for SCENESSE® in Darker-Skinned Patients
Premium
Company Announcements
Clinuvel Reports New Positive Vitiligo Data for SCENESSE® in Darker-Skinned Patients
3M ago
Clinuvel Pharmaceuticals Reports Lapse of 5,425 Performance Rights
Premium
Company Announcements
Clinuvel Pharmaceuticals Reports Lapse of 5,425 Performance Rights
3M ago
Clinuvel Files U.S. GAAP 20-F as It Targets Nasdaq ADR Uplisting
PremiumCompany Announcements
Clinuvel Files U.S. GAAP 20-F as It Targets Nasdaq ADR Uplisting
4M ago
CLINUVEL Expands Singapore RD&I Centre for Advanced Peptide Therapies
PremiumCompany Announcements
CLINUVEL Expands Singapore RD&I Centre for Advanced Peptide Therapies
4M ago
CLINUVEL Targets Mid-2026 for European Filing of NEURACTHEL® Instant
PremiumCompany Announcements
CLINUVEL Targets Mid-2026 for European Filing of NEURACTHEL® Instant
4M ago
Clinuvel Pharmaceuticals Addresses Operational Challenges and Strategic Focus
PremiumCompany Announcements
Clinuvel Pharmaceuticals Addresses Operational Challenges and Strategic Focus
5M ago
CLINUVEL Faces Potential Delays in Nasdaq Uplisting Amid U.S. Government Shutdown
PremiumCompany AnnouncementsCLINUVEL Faces Potential Delays in Nasdaq Uplisting Amid U.S. Government Shutdown
5M ago
Clinuvel Pharmaceuticals Emphasizes Strategic Cash Utilization for Sustained Growth
Premium
Company Announcements
Clinuvel Pharmaceuticals Emphasizes Strategic Cash Utilization for Sustained Growth
6M ago
Clinuvel Pharmaceuticals: Strategic Execution and Growth at 2025 AGM
Premium
Company Announcements
Clinuvel Pharmaceuticals: Strategic Execution and Growth at 2025 AGM
6M ago
Health Canada Extends Review of CLINUVEL’s SCENESSE® for EPP
PremiumCompany Announcements
Health Canada Extends Review of CLINUVEL’s SCENESSE® for EPP
6M ago
CLINUVEL Pharmaceuticals Issues New Shares to Strengthen Market Position
PremiumCompany Announcements
CLINUVEL Pharmaceuticals Issues New Shares to Strengthen Market Position
6M ago
Clinuvel Pharmaceuticals Announces Cessation of Securities
PremiumCompany Announcements
Clinuvel Pharmaceuticals Announces Cessation of Securities
6M ago
Clinuvel Pharmaceuticals Issues Shares to Consultants
PremiumCompany Announcements
Clinuvel Pharmaceuticals Issues Shares to Consultants
6M ago
Clinuvel Pharmaceuticals Announces Quotation of New Securities
PremiumCompany AnnouncementsClinuvel Pharmaceuticals Announces Quotation of New Securities
6M ago
CLINUVEL Pharmaceuticals Announces Management Update and Strategic Focus
Premium
Company Announcements
CLINUVEL Pharmaceuticals Announces Management Update and Strategic Focus
6M ago
CLINUVEL Advances Novel Sustained-Release Drug Formulations
Premium
Company Announcements
CLINUVEL Advances Novel Sustained-Release Drug Formulations
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >